Tags : ixazomib

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM2 Study

Shots: The P-III TOURMALINE-MM2 study involves assessing of Ninlaro + lenalidomide + dexamethasone vs PBO + lenalidomide + dexamethasone in 705 transplant-ineligible patients with newly diagnosed MM The P-III TOURMALINE-MM2 study results: improvement in PFS (35.3 mos. vs 21.8 mos.); safety profile is consistent with the existing prescribing information Ninlaro is an oral proteasome inhibitor, […]Read More

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-MM4 Study

Shots: The P-III TOURMALINE-MM4 study involves assessing Ninlaro (ixazomib) as 1L maintenance therapy vs PBO in 706 newly diagnosed patients with multiple myeloma not treated with stem cell transplantation with completed 6-12mos. of initial therapy and achieved a partial response or better The P-III TOURMALINE-MM4 study results demonstrated significant improvement in PFS with consistent safety […]Read More

Takeda Reports Results of Ninlaro (ixazomib) in P-III TOURMALINE-AL1 Study

Shots: The P-III TOURMALINE-AL1 (NCT01659658) study involves assessing of Ninlaro + dexamethasone vs dexamethasone + (melphalan/ cyclophosphamide/ thalidomide/ lenalidomide)/ monothx in patients with relapsed or refractory systemic light chain (AL) amyloidosis  The P-III TOURMALINE-AL1 study resulted in unmet 1EPs as well as demonstrated no improvement in overall hematologic response leading to its discontinuation Ninlaro (ixazomib) […]Read More